D. N. Franz Et Al. , "Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3," EPILEPSIA , vol.62, no.12, pp.3029-3041, 2021
Franz, D. N. Et Al. 2021. Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3. EPILEPSIA , vol.62, no.12 , 3029-3041.
Franz, D. N., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., ... Curatolo, P.(2021). Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3. EPILEPSIA , vol.62, no.12, 3029-3041.
Franz, David Et Al. "Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3," EPILEPSIA , vol.62, no.12, 3029-3041, 2021
Franz, David N. Et Al. "Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3." EPILEPSIA , vol.62, no.12, pp.3029-3041, 2021
Franz, D. N. Et Al. (2021) . "Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3." EPILEPSIA , vol.62, no.12, pp.3029-3041.
@article{article, author={David N. Franz Et Al. }, title={Adjunctive everolimus therapy for tuberous sclerosis complex-associated refractory seizures: Results from the postextension phase of EXIST-3}, journal={EPILEPSIA}, year=2021, pages={3029-3041} }